MOLN
Molecular Partners AG NASDAQ$4.25
Mkt Cap $159.0M
52w Low $3.41
43.1% of range
52w High $5.36
50d MA $4.46
200d MA $4.12
P/E (TTM)
-2.6x
EV/EBITDA
-0.8x
P/B
2.0x
Debt/Equity
0.1x
ROE
—
P/FCF
-2.5x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$4.46
200d MA
$4.12
Avg Volume
3.2K
About
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.38 | -0.41 | -7.9% | 4.71 | -1.7% | -10.4% | -7.9% | -7.9% | -3.4% | -0.4% | — |
| Oct 30, 2025 | AMC | -0.46 | -0.41 | +10.9% | 3.77 | -0.8% | -3.7% | +8.5% | +3.7% | +6.9% | +24.1% | — |
| Aug 25, 2025 | AMC | -0.53 | -0.67 | -26.4% | 4.22 | -7.6% | -7.8% | -11.1% | -14.7% | -11.1% | -10.0% | — |
| May 15, 2025 | AMC | -0.42 | -0.50 | -18.7% | 3.85 | +1.0% | -0.3% | +2.6% | +2.3% | +2.3% | +1.0% | — |
| Mar 6, 2025 | AMC | -0.44 | -0.34 | +22.7% | 4.90 | -7.3% | +2.2% | -5.3% | -8.2% | -9.8% | -10.4% | — |
| Oct 31, 2024 | AMC | -0.63 | -0.57 | +9.5% | 5.36 | +15.9% | +14.2% | +13.1% | +7.3% | +16.4% | +12.5% | — |
| Aug 26, 2024 | AMC | -1.26 | -0.51 | +59.5% | 6.19 | +2.6% | +11.8% | +2.3% | +4.7% | -8.2% | -8.9% | — |
| May 16, 2024 | AMC | — | -0.39 | — | 3.87 | -1.8% | -2.3% | -3.6% | -7.5% | -1.8% | -1.6% | — |
| Mar 14, 2024 | AMC | -0.97 | -0.68 | +29.9% | 3.87 | +3.1% | +2.3% | +8.3% | +0.0% | +0.3% | +5.2% | — |
| Oct 26, 2023 | AMC | — | -0.40 | — | 3.80 | -1.6% | -1.6% | -7.2% | -7.2% | -4.0% | +9.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.35 | $4.34 | -0.2% | -0.2% | +1.1% | +2.5% | +0.0% | -1.6% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.22 | $4.22 | +0.0% | +2.8% | +2.8% | +7.8% | +11.1% | +8.8% |
| Dec 8 | JP Morgan | Maintains | Neutral → Neutral | — | $4.52 | $4.29 | -5.1% | -7.1% | -4.6% | -5.3% | -0.9% | -4.2% |
| Sep 3 | JP Morgan | Maintains | Neutral → Neutral | — | $3.80 | $3.69 | -2.9% | -2.1% | -6.1% | -5.8% | -5.8% | -2.1% |
| Dec 5 | JP Morgan | Maintains | Neutral → Neutral | — | $4.26 | $4.45 | +4.5% | +2.1% | +5.2% | +5.2% | +0.7% | -6.8% |
| Aug 29 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $6.43 | $5.77 | -10.3% | -5.4% | -8.6% | -8.9% | -11.2% | -10.0% |
| May 25 | Credit Suisse | Upgrade | Underperform → Neutral | — | $6.88 | $7.27 | +5.6% | -0.3% | +1.3% | +12.0% | +10.4% | +6.5% |
| Apr 27 | SVB Leerink | Maintains | Outperform → Outperform | — | $13.89 | $8.75 | -37.0% | -37.4% | -39.5% | -42.0% | -45.3% | -47.4% |
| Jan 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $28.30 | $30.12 | +6.4% | +12.7% | -6.4% | -1.3% | +5.6% | +6.3% |
| Aug 27 | SVB Leerink | Maintains | Outperform → Outperform | — | $19.95 | $20.44 | +2.5% | +1.5% | +2.1% | +5.1% | +4.2% | +5.3% |
Data updated apr 26, 2026 12:59pm
· Source: massive.com